Chart: Long-Term Commitments: The First Mandatory Post-Marketing Trials
Executive Summary
Long-Term Commitments: The First Mandatory Post-Marketing Trials
You may also be interested in...
Roche’s Actemra Postmarket Safety Plan May Obviate Need For REMS
Roche may have staved off the imposition of a REMS for its rheumatoid arthritis candidate Actemra by proposing a robust pharmacovigilance of its own
Post-Market Studies: Even With New Powers, FDA Relies On Firms’ Judgments
BOSTON - When it comes to setting deadlines for completing post-marketing safety studies, industry has the expertise, Office of New Drugs Deputy Director Sandra Kweder told the Drug Information Association meeting on June 24
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011